Solid cancer patients achieve adequate immunogenicity and low rate of severe adverse events after SARS-CoV-2 vaccination고형암 환자는 SARS-CoV-2 백신 접종 후 적절한 면역원성과 낮은 중증 부작용 발생률 달성Article Published on 2022-07-012022-09-11 Journal: Future Oncology [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, 치료제, [키워드] A significant reduction active treatment Adverse adverse events anti-SARS-CoV-2 S1 IgG antibody antibody level antibody levels anticancer anticancer treatment cancer patient Cancer patients Complete Course COVID-19 disease event healthy controls Immune checkpoint inhibitor Immune checkpoint inhibitors immunogenicity Mild mRNA mRNA-based mRNA-based vaccination mRNA-based vaccine participant Patient patients Prevent receiving Result SARS-CoV-2 vaccination SARS-CoV-2 vaccine second dose Seroconversion seroconversion rate serum severe adverse event severe COVID-19 disease Solid solid cancer therapy Treatment vaccination [DOI] 10.2217/fon-2022-0148 PMC 바로가기 [Article Type] Article
Torque teno virus DNA load as a predictive marker of antibody response to a three-dose regimen of COVID-19 mRNA-based vaccine in lung transplant recipientsArticle Published on 2022-07-012022-10-05 Journal: The Journal of heart and lung transplantation : th [Category] COVID19(2023년), SARS, 바이오마커, 변종, 진단, [키워드] 95% confidence interval Analysis Anti-RBD IgG anti-receptor-binding domain Antibody Response Antibody titer association Biomarker BNT162b2 Characteristics COVID-19 COVID-19 vaccine cut-off develop DNA dose doses evaluate Factors Future IgG response Immunosuppression investigated LTR lung transplant lung transplantation marker mRNA vaccine mRNA-1273 mRNA-based vaccine multivariate logistic regression neutralized Neutralizing antibodies non-responders Omicron variant Patient positive Predictive previous study Ratio RBD recipient reflect regimen reported respond poorly responders ROC Curve second dose Seroconversion the antibody response torque torque teno virus Treatment vaccination Vaccine vaccine response viral DNA virus [DOI] 10.1016/j.healun.2022.07.008 [Article Type] Article
Antibody response to the messenger RNA-1273 vaccine (Moderna) in liver transplant recipients간 이식 환자에서 메신저 RNA-1273 백신(모더나)에 대한 항체 반응Article Published on 2022-07-012022-09-12 Journal: Hepatology communications [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] 95% CI 95% confidence interval acute respiratory syndrome Administered anti-S anti-S IgG antibody cause clinical coronavirus coronavirus disease COVID-19 COVID-19 infection develop dose evaluated examined Factor first vaccination Follow-up General population Hepatitis IgG Immunoglobulin Immunological response immunosuppressive include interquartile range laboratory data liver Liver transplantation Logistic regression LTR LTRs median median age men Messenger RNA Moderna MOST Most patient mRNA mRNA-1273 vaccine mRNA-based vaccine Odds ratio Patient positive predict receiving recipient recipients regimen response RNA-1273 SARS-CoV-2 Serologic response shown tested the spike protein the vaccine university Vaccine vaccine dose [DOI] 10.1002/hep4.1937 PMC 바로가기 [Article Type] Article
Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective studyObservational Study Published on 2022-06-212022-10-05 Journal: PLoS Medicine [Category] COVID19(2023년), SARS, 임상, [키워드] 95% CI Administered Adverse adverse event AESI AESIs all-cause mortality Analysis anaphylaxis authority Bell BNT162b2 Characteristics cohort study comparable CoronaVac coronavirus disease country COVID-19 COVID-19 vaccine COVID-19 vaccines cumulative disorder dose electronic medical record event Evidence first dose Follow-up group help Hong Kong inactivated Inactivated vaccine incidence incidence rate include individual individuals limitation Mortality mRNA mRNA vaccines mRNA-based vaccine no significant difference observation period of BNT162b2 Poisson regression models population-based cohort populations rate ratio recipient recipients recorded reduce reported residual confounding retrospective Retrospective study Safety safety profile SARS-CoV-2 vaccine SARS-CoV-2 vaccines second dose significantly higher Surveillance the vaccine Thromboembolism vaccinated individual vaccination Vaccine Vaccine hesitancy Weighting were excluded [DOI] 10.1371/journal.pmed.1004018 PMC 바로가기 [Article Type] Observational Study
Seroprevalence of immunoglobulin G antibodies against SARS-CoV-2 in Cyprus키프로스에서 SARS-CoV-2에 대한 면역글로불린 G 항체의 혈청유병률Article Published on 2022-06-132022-09-12 Journal: PLoS ONE [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] Analysis antibody Antibody Response ChAdOx1 nCoV-19 coronavirus disease COVID-19 Cyprus dose elicit Evidence IgG antibody Immunoglobulin individual infected with SARS-CoV-2 Infection infection with SARS-CoV-2 monitoring mRNA-based mRNA-based vaccine pandemic plasma Previous studies produced public health response responses SARS-CoV-2 SARS-CoV-2 IgG SARS-CoV-2 spike protein Seroprevalence single dose the SARS-CoV-2 the vaccine Vaccine virus Zeneca [DOI] 10.1371/journal.pone.0269885 PMC 바로가기 [Article Type] Article
Humoral response to mRNA vaccines against SARS-CoV-2 in patients with humoral immunodeficiency disease체액성 면역결핍증 환자에서 SARS-CoV-2에 대한 mRNA 백신에 대한 체액 반응Article Published on 2022-06-092022-09-12 Journal: PLoS ONE [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] 95%CI Analysis anti-S anti-S antibody anti-SARS-CoV-2 antibody baseline BNT162b2 cross-sectional CVID dose evaluate evaluated healthy control healthy controls hospitalizations humoral humoral immune response humoral immune responses Humoral response Hypogammaglobulinemia IgG immune response immunodeficiency immunodeficiency disease immunoglobulin replacement therapy immunosuppressive drug immunosuppressive drugs individual induce Infection Mild moderate mRNA vaccine mRNA-1273 mRNA-based vaccine Patient patients patients with moderate Prevent proportion robust SARS-CoV-2 Spike protein subject the antibody response the spike protein vaccination vaccine dose vaccine doses were measured [DOI] 10.1371/journal.pone.0268780 PMC 바로가기 [Article Type] Article
Editorial: Time to explore the missing links: from activated platelets and platelet extracellular vesicles in SARS-CoV-2 infection, through heterogeneity in the host physiological, immuno-inflammatory and haemostatic responses to mRNA-based vaccine or infection induced polyclonal neutralizing antibodies and passive immunity편집자: 누락된 연결을 탐색할 시간: SARS-CoV-2 감염의 활성화된 혈소판 및 혈소판 세포외 소포에서 숙주의 이질성을 통해 mRNA 기반 백신 또는 감염 유도 다클론 중화 항체 및 수동적 생리학적, 면역염증 및 지혈 반응에 대한 반응 면역Editorial Published on 2022-06-012022-09-12 Journal: Transfusion and apheresis science : official journ [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] activated extracellular vesicle heterogeneity Host immuno-inflammatory Infection mRNA-based vaccine neutralizing antibody passive immunity physiological Platelet polyclonal response SARS-COV-2 infection time [DOI] 10.1016/j.transci.2022.103464 PMC 바로가기 [Article Type] Editorial
BNT162b2 vaccine induces antibody release in saliva: a possible role for mucosal viral protection?BNT162b2 백신은 타액에서 항체 방출을 유도합니다: 점막 바이러스 보호를 위한 가능한 역할?Article Published on 2022-05-092022-09-11 Journal: EMBO Molecular Medicine [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] Administered antibody BNT162b2 BNT162b2 vaccine cleaved Concentration Course Decline effective full-length spike protein IgA IgA antibodies IgG Immunity in viral induce Infection mRNA mRNA-based mRNA-based vaccine mucosal mucosal immunity pathogen Pfizer/BioNTech plasma plasma IgG protease PROTECT Saliva SARS-CoV-2 Spike protein subjects systemically vaccination Viral [DOI] 10.15252/emmm.202115326 PMC 바로가기 [Article Type] Article
Persistence of protection against SARS-CoV-2 clinical outcomes up to 9 months since vaccine completion: a retrospective observational analysis in Lombardy, ItalyObservational Study Published on 2022-05-012022-10-04 Journal: The Lancet. Infectious Diseases [Category] COVID19(2023년), SARS, 임상, [키워드] 95% CI accelerated Adenovirus-vectored vaccine analysed Analysis booster change clinical consequences Clinical outcome Complete COVID-19 COVID-19 vaccination Effectiveness forms greater illness incidence rate increase in individual individuals Infection infection rate infections information investigated Italian Italy lombardy measure mRNA-based vaccine Older outcome platform protective effect receiving reduction retrospective risk risk of infection SARS-CoV-2 SARS-COV-2 infection Spread the SARS-CoV-2 trend vaccinated individuals vaccination Vaccine [DOI] 10.1016/S1473-3099(21)00813-6 PMC 바로가기 [Article Type] Observational Study
Anti-SARS-CoV-2 IgA and IgG in human milk after vaccination is dependent on vaccine type and previous SARS-CoV-2 exposure: a longitudinal study백신 접종 후 모유 내 Anti-SARS-CoV-2 IgA 및 IgG는 백신 유형 및 이전 SARS-CoV-2 노출에 따라 다릅니다. 종단 연구Observational Study Published on 2022-04-212022-09-12 Journal: Genome Medicine [Category] COVID19(2023년), SARS, 임상, 진단, [키워드] age anti-SARS-CoV-2 anti-SARS-CoV-2 IgG antibodies antibody AstraZeneca baseline BNT162b2 Breast breast milk ChAdOx1 nCoV-19 collected Course COVID-19 COVID-19 vaccination COVID-19 vaccine dependent on distribution dose evaluate first dose group healthcare human milk IgA IgA antibodies IgA level IgG IgG antibody immunoglobulins Infant lactating lactating women Level Moderna mother mRNA vaccine mRNA-1273 mRNA-based vaccine persistence prospective observational study Protective Protective antibody reactivity receiving SARS-CoV-2 SARS-CoV-2 antibody SARS-COV-2 infection second dose Seven significantly higher Spain the vaccine transfer vaccination Vaccine Vaccines virus women [DOI] 10.1186/s13073-022-01043-9 PMC 바로가기 [Article Type] Observational Study